Antibiotic prophylaxis in reduction mammaplasty: study protocol for a randomized controlled trial

Detalhes bibliográficos
Autor(a) principal: Garcia, Edgard Silva [UNIFESP]
Data de Publicação: 2016
Outros Autores: Veiga, Daniela Francescato [UNIFESP], Veiga-Filho, Joel, Cabral, Isaias Vieira, Larcher Pinto, Natylia Lana, Novo, Neil Ferreira [UNIFESP], Sabino Neto, Miguel [UNIFESP], Ferreira, Lydia Masako [UNIFESP]
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UNIFESP
Texto Completo: http://dx.doi.org/10.1186/s13063-016-1700-y
https://repositorio.unifesp.br/handle/11600/56699
Resumo: Background: The role of antibiotics in surgical procedures where the risk of surgical site infection (SSI) is low remains uncertain. There is, to date, no evidence to justify the routine use of antibiotics in postoperative reduction mammaplasty. The aim of this study is to evaluate the effect of postoperative antibiotic treatment on the occurrence of SSI after breast reduction surgery. Methods: This is a double-blind randomized clinical trial with 124 breast hypertrophy patients allocated to two treatment groups: antibiotic (n = 62) and placebo (n = 62). All patients will undergo reduction mammoplasty, performed by the same surgical team. The surgeons will raise the nipple-areola complex by the superomedial pedicle technique. The patients will receive antibiotics intravenously during anesthetic induction and every 6 hours thereafter during their 24-hour hospital stay. During discharge from the hospital, each patient will receive a numbered package containing either cephalexin or placebo capsules and will be directed to take one capsule every 6 hours for 7 days. Neither the surgery team nor the patients will know the contents of the capsules. Patients will be monitored for the occurrence of SSI once weekly during the first 30 days following hospital discharge by a single surgeon who is blinded to their treatment group. SSI will be evaluated based on the definition adopted by the Centers for Disease Control and Prevention. Discussion: Due to the variety of risk factors for SSI and limited case studies, conclusions regarding the effect of antibiotics on the occurrence of SSIs following reduction mammaplasty are potentially biased. In recent studies, perioperative antibiotic prophylaxis was effective in preventing infection and is therefore recommended in clinical practice. However, antibiotic use in the postoperative period still remains controversial.
id UFSP_57711bac70d5e97463e51dcc85103957
oai_identifier_str oai:repositorio.unifesp.br/:11600/56699
network_acronym_str UFSP
network_name_str Repositório Institucional da UNIFESP
repository_id_str 3465
spelling Antibiotic prophylaxis in reduction mammaplasty: study protocol for a randomized controlled trialPlastic surgeryMammaplastyWound infectionProphylaxisBackground: The role of antibiotics in surgical procedures where the risk of surgical site infection (SSI) is low remains uncertain. There is, to date, no evidence to justify the routine use of antibiotics in postoperative reduction mammaplasty. The aim of this study is to evaluate the effect of postoperative antibiotic treatment on the occurrence of SSI after breast reduction surgery. Methods: This is a double-blind randomized clinical trial with 124 breast hypertrophy patients allocated to two treatment groups: antibiotic (n = 62) and placebo (n = 62). All patients will undergo reduction mammoplasty, performed by the same surgical team. The surgeons will raise the nipple-areola complex by the superomedial pedicle technique. The patients will receive antibiotics intravenously during anesthetic induction and every 6 hours thereafter during their 24-hour hospital stay. During discharge from the hospital, each patient will receive a numbered package containing either cephalexin or placebo capsules and will be directed to take one capsule every 6 hours for 7 days. Neither the surgery team nor the patients will know the contents of the capsules. Patients will be monitored for the occurrence of SSI once weekly during the first 30 days following hospital discharge by a single surgeon who is blinded to their treatment group. SSI will be evaluated based on the definition adopted by the Centers for Disease Control and Prevention. Discussion: Due to the variety of risk factors for SSI and limited case studies, conclusions regarding the effect of antibiotics on the occurrence of SSIs following reduction mammaplasty are potentially biased. In recent studies, perioperative antibiotic prophylaxis was effective in preventing infection and is therefore recommended in clinical practice. However, antibiotic use in the postoperative period still remains controversial.Univ Fed Sao Paulo, Translat Surg Grad Program, Rua Napoleao Barros 725,4th Floor, BR-04024002 Sao Paulo, SP, BrazilUniv Vale Sapucai, Div Plast Surg, Ctr, Rua Comendador Jose Garcia 777, BR-37550000 Pouso Alegre, MG, BrazilTranslational Surgery Graduate Program, Universidade Federal de São Paulo (UNIFESP), Rua Napoleão de Barros, 725, 4th Floor, Vila Clementino, CEP: 04024-002 São Paulo, SP, BrazilWeb of ScienceConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)Fundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG)CNPq: 444087/2014FAPEMIG: APQ-00995-15Biomed Central Ltd2020-07-31T12:47:15Z2020-07-31T12:47:15Z2016info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion-application/pdfhttp://dx.doi.org/10.1186/s13063-016-1700-yTrials. London, v. 17, p. -, 2016.10.1186/s13063-016-1700-yWOS000388901200001.pdf1745-6215https://repositorio.unifesp.br/handle/11600/56699WOS:000388901200001engTrialsLondoninfo:eu-repo/semantics/openAccessGarcia, Edgard Silva [UNIFESP]Veiga, Daniela Francescato [UNIFESP]Veiga-Filho, JoelCabral, Isaias VieiraLarcher Pinto, Natylia LanaNovo, Neil Ferreira [UNIFESP]Sabino Neto, Miguel [UNIFESP]Ferreira, Lydia Masako [UNIFESP]reponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2024-08-11T13:32:17Zoai:repositorio.unifesp.br/:11600/56699Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652024-08-11T13:32:17Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false
dc.title.none.fl_str_mv Antibiotic prophylaxis in reduction mammaplasty: study protocol for a randomized controlled trial
title Antibiotic prophylaxis in reduction mammaplasty: study protocol for a randomized controlled trial
spellingShingle Antibiotic prophylaxis in reduction mammaplasty: study protocol for a randomized controlled trial
Garcia, Edgard Silva [UNIFESP]
Plastic surgery
Mammaplasty
Wound infection
Prophylaxis
title_short Antibiotic prophylaxis in reduction mammaplasty: study protocol for a randomized controlled trial
title_full Antibiotic prophylaxis in reduction mammaplasty: study protocol for a randomized controlled trial
title_fullStr Antibiotic prophylaxis in reduction mammaplasty: study protocol for a randomized controlled trial
title_full_unstemmed Antibiotic prophylaxis in reduction mammaplasty: study protocol for a randomized controlled trial
title_sort Antibiotic prophylaxis in reduction mammaplasty: study protocol for a randomized controlled trial
author Garcia, Edgard Silva [UNIFESP]
author_facet Garcia, Edgard Silva [UNIFESP]
Veiga, Daniela Francescato [UNIFESP]
Veiga-Filho, Joel
Cabral, Isaias Vieira
Larcher Pinto, Natylia Lana
Novo, Neil Ferreira [UNIFESP]
Sabino Neto, Miguel [UNIFESP]
Ferreira, Lydia Masako [UNIFESP]
author_role author
author2 Veiga, Daniela Francescato [UNIFESP]
Veiga-Filho, Joel
Cabral, Isaias Vieira
Larcher Pinto, Natylia Lana
Novo, Neil Ferreira [UNIFESP]
Sabino Neto, Miguel [UNIFESP]
Ferreira, Lydia Masako [UNIFESP]
author2_role author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Garcia, Edgard Silva [UNIFESP]
Veiga, Daniela Francescato [UNIFESP]
Veiga-Filho, Joel
Cabral, Isaias Vieira
Larcher Pinto, Natylia Lana
Novo, Neil Ferreira [UNIFESP]
Sabino Neto, Miguel [UNIFESP]
Ferreira, Lydia Masako [UNIFESP]
dc.subject.por.fl_str_mv Plastic surgery
Mammaplasty
Wound infection
Prophylaxis
topic Plastic surgery
Mammaplasty
Wound infection
Prophylaxis
description Background: The role of antibiotics in surgical procedures where the risk of surgical site infection (SSI) is low remains uncertain. There is, to date, no evidence to justify the routine use of antibiotics in postoperative reduction mammaplasty. The aim of this study is to evaluate the effect of postoperative antibiotic treatment on the occurrence of SSI after breast reduction surgery. Methods: This is a double-blind randomized clinical trial with 124 breast hypertrophy patients allocated to two treatment groups: antibiotic (n = 62) and placebo (n = 62). All patients will undergo reduction mammoplasty, performed by the same surgical team. The surgeons will raise the nipple-areola complex by the superomedial pedicle technique. The patients will receive antibiotics intravenously during anesthetic induction and every 6 hours thereafter during their 24-hour hospital stay. During discharge from the hospital, each patient will receive a numbered package containing either cephalexin or placebo capsules and will be directed to take one capsule every 6 hours for 7 days. Neither the surgery team nor the patients will know the contents of the capsules. Patients will be monitored for the occurrence of SSI once weekly during the first 30 days following hospital discharge by a single surgeon who is blinded to their treatment group. SSI will be evaluated based on the definition adopted by the Centers for Disease Control and Prevention. Discussion: Due to the variety of risk factors for SSI and limited case studies, conclusions regarding the effect of antibiotics on the occurrence of SSIs following reduction mammaplasty are potentially biased. In recent studies, perioperative antibiotic prophylaxis was effective in preventing infection and is therefore recommended in clinical practice. However, antibiotic use in the postoperative period still remains controversial.
publishDate 2016
dc.date.none.fl_str_mv 2016
2020-07-31T12:47:15Z
2020-07-31T12:47:15Z
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://dx.doi.org/10.1186/s13063-016-1700-y
Trials. London, v. 17, p. -, 2016.
10.1186/s13063-016-1700-y
WOS000388901200001.pdf
1745-6215
https://repositorio.unifesp.br/handle/11600/56699
WOS:000388901200001
url http://dx.doi.org/10.1186/s13063-016-1700-y
https://repositorio.unifesp.br/handle/11600/56699
identifier_str_mv Trials. London, v. 17, p. -, 2016.
10.1186/s13063-016-1700-y
WOS000388901200001.pdf
1745-6215
WOS:000388901200001
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Trials
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv -
application/pdf
dc.coverage.none.fl_str_mv London
dc.publisher.none.fl_str_mv Biomed Central Ltd
publisher.none.fl_str_mv Biomed Central Ltd
dc.source.none.fl_str_mv reponame:Repositório Institucional da UNIFESP
instname:Universidade Federal de São Paulo (UNIFESP)
instacron:UNIFESP
instname_str Universidade Federal de São Paulo (UNIFESP)
instacron_str UNIFESP
institution UNIFESP
reponame_str Repositório Institucional da UNIFESP
collection Repositório Institucional da UNIFESP
repository.name.fl_str_mv Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)
repository.mail.fl_str_mv biblioteca.csp@unifesp.br
_version_ 1814268350200545280